Purpose: Five-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists (RAs) are widely used to control chemotherapy-induced nausea and vomiting in cancer chemotherapy. Several 5-HT 3 RAs could be available, there are some important points to select agents, like as efficacy, adverse events and their costs. In this study, we compared an originator drug, azasetron with a generic version, granisetronNK, to evaluate their anti-emetic efficacy and quality of life in crossover randomized setting.
Introduction
Chemotherapy-induced nausea and vomiting (CINV) is a major adverse event in cancer chemotherapy 1) . CINV has a strong negative effect on patient quality of life (QOL) and can limit the efficacy of cancer treatments due to discontinuation. Administration of adequate supportive therapy for CINV may prevent dose reduction of chemotherapeutic agents and keep dose intensity, which may contribute to improvement in therapeutic effects and prognosis of the cancer patients.
Anticancer agents have been classified for several groups depending on their risk of CINV, based on evidences from randomized clinical trials. Some clinical guidelines recommend optimal treatments to prevent CINV for each group 2), 3) . Five-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists (RAs) are preferred in high emetic risk and moderate emetic risk, in combination with corticosteroids and/or neurokinin 1 (NK1) antagonist.
Several 5-HT 3 RAs are commercially available, and appear to have no difference in terms of preventing CINV 3) . In clinical use, both efficacy and drug cost are important factors in therapeutic decision-making process. Generic substitution was introduced with the aim of curbing the rise in medical expenses for society and individuals. A population-based survey showed that price, familiarity, and availability were important factors in the choice of prescribed medicines, whereas the external characteristics of the medicines, i.e, the colour and shape of the tablet/capsule and/or the appearance of the package, were not significant factor for choosing the drug 4) . Although generic products do clearly have the potential to offer tremendous cost-savings for patients, this benefit is based on the assumption that a generic product displays essentially the same kinetic and dynamic profile as that of its brand-name counterpart 5) . Azasetron is a 5-HT 3 RA and its antiemetic potency is reported as similar to those of granisetron and ondansetron, although the cost is about 10% lower than granisetron [6] [7] [8] . Therefore, in Japan, azasetron is widely used to prevent CINV in cancer chemotherapy. Granisetron NK is one of generic subscription of 5-HT 3 RA and which cost is 69% of azasetron. In this study, we compared granisetron NK and azasetron in terms of their efficacy to prevent CINV. This is first prospective randomized crossover study comparing efficacy and adverse events of generic drug granisetronNK and originater drug azasetron.
Patients and Methods
This study was designed as a single-institution, randomized, single-blind, crossover trial, and approved by Institutional Review Board of Aizawa Hospital based on ethical norms presented in Helsinki Declaration of the World Medical Association as well as under the provisions of Act on the Protection of Personal Information in Japan.Informed consent was obtained from each participant.
Patients
Patients 20 years or older with breast cancer who were preparing to initiate FEC100 (high emetic risk) treatment with a Performance Status score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale were enrolled. Study exclusion criteria were ECOG PS 3 or 4, with severe hepatic, renal, or cardiac diseases as complications, pregnancy or breastfeeding, other cause of nausea or vomiting and receiving radiotherapy during this study.
Treatment
Eligible patients were randomly assigned to 2 treatment groups which receiving granisetronNK in first course of FEC100 regimen followed by receiving azasetron in second course and the other patients receive azasetron in first course followed by granisetronNK in second course. GranisetronNK 3 mg and azasetron 10 mg were mixed with dexamethasone and intravenously infused over 30 minutes before administration of FEC100 regimen (5-FU (500 mg/m 2 ), Epirubicin Hydrochloride (100 mg/m 2 ) and Cyclophosphamide Hydrate (500 mg/ m 2 ) on day 1, every 3 weeks). Granisetron hydrochloride 2 mg and dexamethasone 8 mg were per orally administered for three days after FEC100 regimen. Patients permitted to use additional granisetron hydrochloride 2 mg and/or metoclopramide when they feel CINV, and instructed to record the time and frequency of use their drugs in questionnaire.
Evaluation
Anti-emetic efficacy and adverse events were evaluated using patient questionnaire. Patients were instructed to record their nausea, vomiting, eating status, constipation and additional use of granisetron hydrochloride 2 mg or metoclopramide over a 24-hour period after FEC100 regimen (Table 1) . Patients' QOL during treatment were scored by Numerical Rating Scale (NRS) with 11 scores from 0 to 10. Score 0 represents QOL did not suffered from CINV, and score 10 represents maximum QOL suffering from CINV.
Statistical Analysis
Primary end point was grade and number of CINV treating with granisetronNK compared with that of azasetron. As secondary end points, we analyzed adverse events and QOL.
The severity and frequency of nausea, vomiting, constipation and eating status were analysed using χ 2 -test. QOL was analysed by unpaired t-test. Differences were considered significant if P < 0.05.
Results

Patient characteristics
Between March 2009 and April 2010, 27 breast cancer patients were randomly assigned to receive granisetronNK in first course followed by azasetron in second course and to receive azasetron in first course followed by granisetronNK in second course on the same day of initiation of FEC100 treatment. Thirteen patients first received granisetronNK, and 14 patients first received azasetron. There were no significant differences between the granisetronNK treatment-first group and azasetron treatment-first group in terms of age, sex, body weight, body mass index (BMI), treatment period (neoadjuvant or adjuvant) and dose reduction of FEC100 regimen (Table 2) .
Anti-emetic efficacy
All patients received FEC100 regimen felt nausea in two groups. There were no significant differences about grade and frequency of CINV in both between 2 groups, and between first course and second course (Table 3) . About vomiting, same tendencies were observed (data not shown). Eating status was evaluated as grade1; could eat just like usual amount, grade2; could eat half of usual mount and grade3; could not eat. In the view of comparison of granisetronNK first group and azasetron first group, and comparison of first course and second course, there was no significant difference (Table 4) . Please answer the following question regarding the extent of your suffering within 24 hours of the infusion. With the score of 10 representing the worst suffering related to vomiting and feeling nausea that you can imagine, how do you rate your current suffering? Please mark the location on the scale that best represents your situation with a circle.
No suffering
Worst suffering 10 0 5
Adverse events Adverse events including constipation which is considered as inhibitory action of intestinal movement caused by 5-HT 3 RAs were investigated 5) . There was no difference between 2 groups (Table 5) . No patients discontinued treatment due to adverse events and all of them completed the scheduled treatment.
QOL analysis during treatment
In QOL analysis, granisetronNK first group showed score 1.8 (+-1.9) and azasetron first group showed score 3.1(+-2.3) in first course of treatment (Fig. 1) . Statically analysis using unpaired t-test showed no difference between two groups.
Discussion
This randomized crossover study revealed no significant differences between Granisetron NK (a generic) and azasetron (an originator drug) in terms of efficacy, adverse events and QOL.
In this study, we selected FEC regimen classified as high emetic risk to investigate of preventing effect of two 5-HT 3 RAs. After 2006, even though NK-1 inhibitors have been recommended for high emetic risk groups, 5-HT 3 RAs and corticosteroids are also needed 2), 3), 9) . Currently 5-HT 3 RAs are recommended as an established regimen for moderate emetic risk combined with corticosteroids 3), 4) . Thus 5-HT 3 RAs play important roles in anti-emetic treatment for cancer chemotherapy.
Although, several 5-HT 3 RAs can be commercially available, it is important to confirm their efficacy and adverse event in clinical use 3) . Therefore we conducted this clinical trial to compare a generic anti-emetic drug and an originator drug in crossover design.
The reasons we selected a crossover design are follows. At first, nausea and vomiting are subjective symptoms with extremely high individual variability, it is desirable to implement the trial with the same subject; second, that their maximum drug concentration time (Tmax) of two arms are post-dosage, and are quickly eliminated thereafter with half-lives within five hours, therefore washout period are provided in the 21-day dosage interval of FEC100 treatment.
In the view point of medical economy, cost of granisetronNK is 69% of that of azasetron. About 1500 Japanese yen (about 12-18 US dollars) was saved per one vial. Four cycles of FEC100 regimen could save about 6000 Japanese yen (about 48-72 US dollars) for one patient. As described above, 5-HT 3 RAs are widely used for low to high emetic risk chemotherapy regimens for various cancers. Even though cost reduction for one patient is not so big, whole of society, the cost reduction effect might be very big. It will be more important to investigate generic drugs in terms of the balance of their efficacy and drug cost.
Limitation of this study is first, the patient number is too small to make a conclusion that granisetronNK is clinically equal to azasetron, and second, lack of view point of QOL including not only physical status but also patient's economical feeling. Although balance of drug efficacy and cost is very important, we don't have adequate scale or criteria to evaluate both factors. If the adequate scale or criteria were added, research and develop of generic drugs will be clearer.
Conclusions
A generic 5-HT 3 RAs granisetronNK which reduce 31% drug cost showed no significant difference in efficacy, adverse events and QOL compared with originator drug azasetron in randomized crossover study. Rating Scale (NRS) with 11 scores from 0 to 10. Score 0 represents QOL did not suffered from CINV, and score 10 represents maximum QOL suffering from CINV. There was no significant difference between granisetronNK first group and azasetron first group (unpaired t-test; n.s.). 
